Current and emerging azole antifungal agents

Clinical Microbiology Reviews

Volumn 12, Issue 1, 1999, Pages 40-79

  Sheehan, Daniel J ^a   Hitchcock, Christopher A ^b   Sibley, Carol M ^c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Med/Scientific Communications Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE; TRIAZOLE DERIVATIVE;

DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HUMAN; MYCOSIS; OPPORTUNISTIC INFECTION; REVIEW;

EID: 0032960378     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.12.1.40     Document Type: Review

References (274)

1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128.
2. Alangaden, G., P. H. Chandrasekar, E. Bailey, Y. Khaliq, and the Bone Marrow Transplantation Team. 1994. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplant. 14:919-924.
3. Aly, R., and T. Berger. 1996. Common superficial fungal infections in patients with AIDS. Clin. Infect. Dis. 22:S128-S132.
4. Anaissie, E. J., R. O. Darouiche, D. Abi-Said, O. Uzun, J. Mera, L. O. Gentry, T. Williams, D. P. Kontoyiannis, C. L. Karl, and G. P. Bodey. 1996. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. 23:964-972.
5. Anaissie, E. J., V. L. Paetznick, L. G. Ensign, A. Espinel-Ingroff, J. N. Galgiani, C. A. Hitchcock, M. LaRocco, T. Patterson, M. A. Pfaller, and J. H. Rex, et al. 1996. Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study. Antimicrob. Agents Chemother. 40: 2387-2391.
6. Anaissie, E. J., J. H. Rex, O. Uzun, and S. Vartivarian. 1998. Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med. 104:238-245.
7. Anaissie, E. J., S. E. Vartivarian, D. Abi-Said, O. Uzun, H. Pinczowski, D. P. Kontoyiannis, P. Khoury, K. Papadakis, A. Gardner, I. I. Raad, et al. 1996. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. 101:170-176.
8. Arikian, S. R., T. R. Einarson, G. Kobelt-Nguyen, F. Schubert, and the Onymychosis Study Group. 1994. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br. J. Dermatol. 130(Suppl. 43):35-44.
9. Assaf, R. R., and B. E. Elewski. 1996. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J. Am. Acad. Dermatol. 35:216-219.
10. Barchiesi, F., L. F. Di Francesco, and G. Scalise. 1997. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41:1812-1814.
11. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949.
12. Bartlett, J. G. 1998. Medical management of HIV infection. Department of Infectious Diseases, Johns Hopkins University, Baltimore, Md.
13. Bartroli, J., E. Turmo, M. Algueró, E. Boncompte, M. L. Vericat, J. García-Rafanell, and J. Forn. 1995. Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring. J. Med. Chem. 38:3918-3932.
14. Benedetti, E., A. C. Gruessner, C. Troppmann, B. E. Papalois, D. E. R. Sutherland, D. L. Dunn, and R. W. G. Gruessner. 1996. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J. Am. Coll. Surg. 183:307-316.
15. Bennett, J. E. 1995. Antifungal agents, p. 401-410. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
16. Bennett, J. E. 1995. Aspergillus species, p. 2306-2311. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
17. Bennett, J. E. 1995. Miscellaneous fungi, and Prototheca, p. 2389-2393. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
18. Bennett, J. E. 1996. Antifungal agents, p. 1175-1190. In G. J. G. Hardman, L. E. Limbird, P. B. Molenoff, R. W. Ruddon, and A. G. Gilman (ed.), Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. McGraw-Hill Book Co., New York, N.Y.
19. Berry, A. J., M. G. Rinaldi, and J. R. Graybill. 1992. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob. Agents Chemother. 36:690-692.
20. Billstein, S. A. 1994. How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob. Agents Chemother. 38: 2679-2682.
21. Bodey, G. P. 1992. Azole antifungal agents. Clin. Infect. Dis. 14(Suppl. 1):S161-S169.
22. Bonnotte, B., D. Caillot, E. Solary, J. Lopez, C. Bailly, O. Casanovas, P. Chavanet, A. Bonnin, and H. Guy. 1994. Breakthrough candidemias in patients with haematological malignancies during antifungal azole prophylaxis. A report of 20 cases. J. Infect. 8:59. (Abstract.)
23. Bornay-Llinares, F. J., M. S. Mayol-Belda, J. Onrubia-Pintado, and J. M. Torres-Rodriguez. 1995. Murine cryptococcosis. Tissular damage decreases after treatment with UR-9746, abstr. F88, p. 128. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Bornay-Llinares, F. J., and J. M. Torres-Rodriguez. 1995. Anticryptococcal activity of a new azole derivative (UR-9746) in a murine model, abstr. F86, p. 128. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
25. Boschman, C. R., U. R. Bodnar, M. A. Tornatore, A. A. Obias, G. A. Noskin, K. Englund, M. A. Postelnick, T. Suriano, and L. R. Peterson. 1998. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob. Agents Chemother. 42:734-738.
26. Bozzette, S. A., R. Larsen, J. Chiu, M. A. E. Leal, J. Jacobsen, P. Rothman, P. Robinson, G. Gilbert, J. A. McCutchan, J. Tilles, et al. 1991. A controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324:580-584.
27. Bradsher, R. W. 1996. Histoplasmosis and blastomycosis. Clin. Infect. Dis. 22(Suppl. 2):S102-S111.
28. Budavari, S. (ed.). 1989. The Merck index. Merck & Co., Inc., Rahway, N.J.
29. Bullock, W. E. 1995. Histoplasma capsulatum, p. 2340-2353. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N. Y.
30. Cacciapuoti, A., D. Loebenberg, D. Frank, E. L. J. Moss, F. Menzel, M. Michalski, C. Norris, B. Yaremko, R. S. Hare, and G. H. Miller. 1996. Effect of delayed or extended treatment with SCH56592 (SCH) or concomitant treatment with amphotericin B (AMB) in murine models of pulmonary aspergillosis and systemic candidiasis, abstr. F96, p. 116. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
31. Cacciapuoti, A., R. Parmegiani, D. Loebenberg, B. Antonacci, E. L. J. Moss, F. J. Menzel, C. Norris, R. S. Hare, and G. H. Miller. 1995. Efficacy of SCH 56592 in pulmonary aspergillosis and candidiasis in mice, abstr. F66, p. 124. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
32. Cartledge, J. D., J. Midgely, and B. G. Gazzard. 1997. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J. Clin. Pathol. 50:477-480.
33. Cartledge, J. D., J. Midgley, and B. G. Gazzard. 1997. Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS 11:163-168.
34. Castagnola, E., B. B, E. Montinaro, and C. Viscoli. 1996. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol. Bone Marrow Transplant. 18(Suppl. 2):97-106.
35. Catanzaro, A., J. N. Galgiani, B. E. Levine, P. K. Sharkey-Mathis, J. Fierer, D. A. Stevens, S. W. Chapman, G. Cloud, and NIAID Mycoses Study Group. 1995. Fluconazole in the treatment of chronic pulmonary and non-meningeal disseminated coccidioidomycosis. Am. J. Med. 98:249-256.
36. Centers for Disease Control and Prevention. 1998. 1998 guidelines for treatment of sexually transmitted diseases. Morbid. Mortal. Weekly Rep. 47(RR-1):75-79.
37. Chapman, S. W. 1995. Blastomyces dermatitidis, p. 2353-2365. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
38. Chin, N.-X., I. Weitzman, and P. Della-Latta. 1997. In vitro antifungal activity of voriconazole alone and in combination with flucytosine against Candida species and other pathogenic fungi, abstr. E-84, p. 128. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
39. Clancy, C. J., C. Y. Yu, and M. H. Nguyen. 1997. In vitro activity of voriconazole against yeasts and comparison with fluconazole, abstr. E-88, p. 129. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
40. Clancy, C. J., Y. C. Yu, and M. H. Nguyen. 1997. Comparison of in vitro activity of voriconazole and amphotericin B against filamentous fungi, abstr. E-89, p. 129. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
41. Clemons, K. V., L. H. Hanson, and D. A. Stevens. 1993. Activities of the triazole D0870 in vitro against murine blastomycosis. Antimicrob. Agents Chemother. 37:1177-1179.
42. Clemons, K. V., and D. A. Stevens. 1997. Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidioidomycosis. Antimicrob. Agents Chemother. 41:200-203.
43. Cohen, P. R., and R. K. Scher. 1994. Topical and surgical treatment of onychomycosis. J. Am. Acad. Dermatol. 31:S74-S77.
44. Coldiron, B. 1992. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch. Dermatol. 128:909-910.
45. Cole, G. T., K. R. Seshan, and D. Loebenberg. 1996. Evaluation of SCH 56592 in clearance of GI mucosal candidiasis from mice with retroviral-induced immunodeficiency, abstr. F95, p. 116. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
46. Colombo, A. L., F. Barchiesi, D. A. McGough, and M. G. Rinaldi. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J. Clin. Microbiol. 33:535-540.
47. Como, J. A., and W. E. Dismukes. 1994. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330:263-272.
48. DeDoncker, P., J. Decroix, G. E. Pierard, D. Roelant, R. Woestenborghs, P. Jacqmin, F. Odds, A. Heremans, P. Dockx, and D. Roseeuw. 1996. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch. Dermatol. 132:34-41.
49. Degreef, J. H., and P. R. G. DeDoncker. 1994. Current therapy of dermatophytosis. J. Am. Acad. Dermatol. 31:S25-S30.
50. deLalla, F., G. Pellizzer, A. Vaglia, V. Manfrin, M. Franzetti, P. Fabris, and C. Stecca. 1995. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin. Infect. Dis. 20:263-266.
51. Del Favero, A., F. Menichetti, A. Micozzi, G. Bucaneve, K. De Buele, P. Martino, and the GIMEMA Infection Program. 1997. Antifungal prophylaxis in neutropenic patients (<1,000/mmc) with haematologic malignancy: a double-blind trial to compare itraconazole oral solution (IOS) with placebo (PLA), abstr. LM-84, p. 380. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
52. Denning, D., A. del Favero, E. Gluckman, D. Norflok, M. Ruhnke, S. Yonren, P. Troke, N. Sarantis, and the Aspergillosis Study Group. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80, p. 126. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
53. Denning, D. W., J. Y. Lee, J. S. Hostetler, P. Pappas, C. A. Kauffman, D. H. Dewsnup, J. N. Galgiani, J. R. Graybill, A. M. Sugar, A. Catanzaro, et al. 1994. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 97:135-144.
54. Denning, D. W., and D. A. Stevens. 1990. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12:1147-1201.
55. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41: 1364-1368.
56. DeWit, S., B. Dupont, J. D. Cartledge, D. A. Hawkins, B. G. Gazzard, N. Clumeck, and D. W. Denning. 1997. A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. AIDS 11:759-763.
57. Diamond, D. M., M. Bauer, B. E. Daniel, M. A. E. Leal, D. Johnson, B. K. Williams, A. M. Thomas, J. C. Ding, L. Najvar, J. R. Graybill, et al. 1998. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob. Agents Chemother. 42:528-533.
58. Diamond, R. D. 1995. Cryptococcus neoformans, p. 2331-2340. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.). Principles and practice of infectious disease, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
59. Diaz, M., R. Negroni, F. Montero-Gei, L. G. M. Castro, S. A. P. Sampaio, D. Borelli, A. Restrepo, L. Franco, J. L. Bran, E. G. Arathoon, et al. 1992. A pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin. Infect. Dis. 14(Suppl. 1):S68-S76.
60. Dickinson, R. P., A. S. Bell, C. A. Hitchcock, S. Narayanaswami, S. J. Ray, K. Richardson, and P. F. Troke. 1996. Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus. Bioorg. Med. Chem. Lett. 6:2031-2036.
61. Ding, J. C., M. Bauer, D. M. Diamond, M. A. E. Leal, D. Johnson, B. K. Williams, A. M. Thomas, L. Majvar, J. R. Graybill, and R. A. Larsen. 1997. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41:1589-1593.
62. Dismukes, W. E. 1993. Management of cryptococcosis. Clin. Infect. Dis. 17(Suppl. 2):S507-S512.
63. Dismukes, W. E., R. W. Bradsher Jr., G. C. Cloud, C. A. Kauffman, S. W. Chapman, R. B. George, D. A. Stevens, W. M. Girard, M. S. Saag, C. Bowles-Patton, et al. 1992. Itraconazole therapy for blastomycosis and histoplasmosis. Am. J. Med. 93:489-497.
64. Drake, L. A., S. M. Dinehart. E. R. Farmer, R. W. Goltz, G. F. Graham, M. K. Hordinsky, C. W. Lewis, D. M. Pariser, J. W. Skouge, S. B. Webster, et al. 1996. Guidelines of care for superficial mycotic infections of the skin: mucocutaneous candidiasis. J. Am. Acad. Dermatol. 34:110-115.
65. Drake, L. A., S. M. Dinehart. E. R. Farmer, R. W. Goltz, G. F. Graham, M. K. Hordinsky, C. W. Lewis, D. M. Pariser, J. W. Skouge, S. B. Webster, et al. 1996. Guidelines of care for superficial mycotic infections of the skin: onychomycosis. J. Am. Acad. Dermatol. 34:116-121.
66. Drake, L. A., S. M. Dinehart, E. R. Farmer, R. W. Goltz, G. F. Graham, M. K. Hordinsky, C. W. Lewis, D. M. Pariser, J. W. Skouge, S. B. Webster, et al. 1996. Guidelines of care for superficial mycotic infections of the skin: piedra. J. Am. Acad. Dermatol. 34:122-124.
67. Drake, L. A., S. M. Dinehart, E. R. Farmer, R. W. Goltz, G. F. Graham, M. K. Hordinsky, C. W. Lewis, D. M. Pariser, J. W. Skouge, S. B. Webster, et al. 1996. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J. Am. Acad. Dermatol. 34:287-289.
68. Drake, L. A., S. M. Dinehart, E. R. Farmer, R. W. Goltz, G. F. Graham, M. K. Hordinsky, C. W. Lewis, D. M. Pariser, J. W. Skouge, S. B. Webster, et al. 1996. Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. J. Am. Acad. Dermatol. 34:290-294.
69. Drake, L. A., S. M. Dinehart, E. R. Farmer, R. W. Goltz, G. F. Graham, M. K. Hordinsky, C. W. Lewis, D. M. Pariser, J. W. Skouge, S. B. Webster, et al. 1996. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J. Am. Acad. Dermatol. 34:282-286.
70. Dromer, F., S. Mathoulin, B. Dupont, O. Brugiere, L. Letenneur, and the French Cryptococcosis Study Group. 1996. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of Cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. Clin. Infect. Dis. 22(Suppl. 2):S154-S160.
71. Dupont, B., D. Denning, H. Lode, S. Youren, P. Troke, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis, abstr. F81, p. 127. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
72. Dupont, B. F., F. Dromer, and L. Improvisi. 1996. The problem of azole resistance in Candida. J. Mycol. Med. 6(Suppl. II):12-19.
73. Edwards, J. E. J. 1995. Candida species, p. 2289-2306. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.). Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
74. Edwards, J. E. J., G. P. Bodey, R. A. Bowden, T. Büchner, B. E. de Pauw, S. G. Filler, M. A. Ghannoum, M. Glauser, R. Herbrecht, C. A. Kauffman, et al. 1997. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. 25:43-59.
75. Elewski, B. E., and R. J. Hay. 1996. Cutaneous antifungal therapy in AIDS: summary of an international summit. Infect. Dis. Clin. Pract. 5:359-370.
76. Elmets, C. A. 1994. Management of common superficial fungal infections in patients with AIDS. J. Am. Acad. Dermatol. 31:S60-S63.
77. Espinel-Ingroff, A. 1994. Etest for antifungal susceptibility testing of yeasts. Diagn. Microbiol. Infect. Dis. 19:217-220.
78. Espinel-Ingroff, A. 1996. Antifungal susceptibility testing. Clin. Microbiol. Newsl. 18:161-167.
79. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, M. Rinaldi, et al. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:314-319.
80. Espinel-Ingroff, A., C. W. J. Kish, T. M. Kerkering, R. A. Fromtling, K. Bartizal, J. N. Galgiani, K. Villareal, M. A. Pfaller, T. Gerarden, M. G. Rinaldi, et al. 1992. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J. Clin. Microbiol. 30:3138-3145.
81. Fessel, W. J., K. W. Merrill, D. J. Ward, B. L. Moskovitz, C. Benken, N. Oleka, and H. Grimwood. 1997. Itraconazole oral solution (IS) for the treatment of fluconazole-refractory oropharyngeal candidiasis (OC) in HIV-positive patients, abstract. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., 22 to 26 January 1997.
82. Fidel, P. L. J., J. L. Cutright, and J. D. Sobel. 1997. Efficacy of D0870 treatment of experimental Candida vaginitis. Antimicrob. Agents Chemother. 41:1455-1459.
83. Fothergill, A. W., D. A. Sutton, and M. G. Rinaldi. 1996. An in vitro head-to-head comparison of Schering 56592, Amphotericin B, Fluconazole, and Itraconazole against a spectrum of filamentous fungi, abstr. F89, p. 115. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
84. Frieden, I. J., and R. Howard. 1994. Tinea capitis: epidemiology, diagnosis, treatment, and control. J. Am. Acad. Dermatol. 31:S42-S46.
85. Fromtling, R. A. 1988. Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev. 1:187-219.
86. Fromtling, R. A., and J. Castaner. 1996. SCH-56592. Drugs Future 21:160-166.
87. Fromtling, R. A., J. N. Galgiani, M. A. Pfaller, A. Espinel-Ingroff, K. F. Bartizal, M. S. Bartlett, B. A. Body, C. Frey, G. Hall, G. D. Roberts, et al. 1993. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob. Agents Chemother. 37:39-45.
88. Fung-Tome, J. C., and D. P. Bonner. 1997. Recent developments in pradimicin-benanomicin and triazole antibiotics. Exp. Opin. Investig. Drugs 6:129-145.
89. Fung-Tome, J. C., E. Huczko, B. Minassian, and D. P. Bonner. 1998. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 42:313-318.
90. Galgiani, J. N., A. Catanzaro, G. A. Cloud, J. Higgs, B. A. Friedman, R. A. Larsen, J. R. Graybill, and the NIAD Mycoses Study Group. 1993. Fluconazole therapy for coccidioidal meningitis. Ann. Inter. Med. 119:28-35.
91. Galgiani, J. N., and M. L. Lewis. 1997. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and othet pathogenic yeast. Antimicrob. Agents Chemother. 41:180-183.
92. Gallis, H. A. 1996. Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clin. Infect. Dis. 22(Suppl. 2):S145-S147
93. George, D., P. Miniter, and V. T. Andriole. 1996. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemothsr. 40:86-91.
94. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
95. Ghannoum, M. A. 1997. Future of antimycotic therapy. Dermatol. Ther. 3:104-111.
96. Ghannoum, M. A., J. H. Rex, and J. N. Galgiani. 1996. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. 34:489-495.
97. Gibb, A. P., C. Thorsten, and H. Van Den Elzen. 1997. No increase in frequency of antifungal resistance among yeasts isolated from sterile sites, Foothills Hospital, Calgary, 1993-1996, abstr. E-76, p. 127. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
98. Glasmacher, A., C. Hahn, K. Molitor, R. Kleinschmidt, and G. Marklein. 1997. Itraconazole in antifungal prophylaxis: comparison of trough levels in neutropenic patients receiving capsules and oral solution, abstract. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September to 1 October 1997.
99. Goa, K. L., and L. B. Barradell. 1995. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50:658-690.
100. Goff, D. A., S. L. Koletar, B. W. J, J. Barnishan, and R. J. Fass. 1995. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin. Infect. Dis. 20:77-83.
101. Grant, S. M., and S. P. Clissold. 1989. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37:310-344.
102. Grant, S. M., and S. P. Clissold. 1990. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39:877-916.
103. Graybill, J. R. 1996. The future of antifungal therapy. Clin. Infect. Dis. 22(Suppl. 2):S166-S178.
104. Graybill, J. R. 1997. Editorial response: can we agree on the treatment of candidiasis? Clin. Infect. Dis. 25:60-62.
105. Graybill, J. R., L. K. Najvar, J. D. Holmberg, and M. F. Luther. 1995. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob. Agents Chemother. 39:924-929.
106. Graybill, J. R., D. A. Stevens, J. N. Galgiani, W. E. Dismukes, G. A. Cloud, and the NIAID Mycoses Study Group. 1990. Itraconazole treatment of coccidioidomycosis. Am. J. Med. 89:282-290.
107. Graybill, J. R., J. Vazques, R. O. Darouiche, R. Morhart, D. Greenspan, C. Tuazon, J. Wheat, J. Carey, I. Leviton, R. G. Hewitt, et al. 1998. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am. J. Med. 104:33-39.
108. Greenspan, D. 1994. Treatment of oropharyngeal candidiasis in HIV-positive patients. J. Am. Acad. Dermatol. 31:S51-S55.
109. Gupta, A. K., D. N. Sauder, and N. H. Shear. 1994. Antifungal agents: an overview. I. J. Am. Acad. Dermatol. 30:677-698.
110. Hadley, S., and A. W. Karchmer. 1995. Fungal infections in solid organ transplant recipients. Infect. Dis. Clin. North Am. 9:1045-1074.
111. Haria, M., H. M. Bryson, and K. L. Goa. 1996. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51:586-620.
112. Hata, K., J. Kimura, H. Miki, T. Toyosawa, M. Moriyama, and K. Katsu. 1996. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 40:2243-2247.
113. Hata, K., J. Kimura, H. Miki, T. Toyosawa, T. Nakamura, and K. Katsu. 1996. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. 40:2237-2242.
114. Hata, K., J. Uneo, H. Miki, T. Toyosawa, K. Katsu, T. Nakamura, and T. Horie. 1995. ER-30346, a novel antifungal triazole. III. In vitro activity and its mode of action, abstr. F92, p. 129. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
115. Haubrich, R. H., D. Haghighat, S. A. Bozzette, J. Tilles, J. A. McCutchan, and the California Collaborative Treatment Group. 1994. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J. Infect. Dis. 170:238-242.
116. Hay, R. J. 1993. Onychomycosis. Agents of choice. Dermatol. Clin. 11:161-169.
117. Hay, R. J. 1995. Dermatophytosis and other superficial mycoses, p. 2375-2386. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.). Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
118. He, X., R. N. Tiballi, L. T. Zarins, S. F. Bradley, J. A. Sangeorzan, and C. A. Kauffman. 1994. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:2495-2497.
119. Heald, A. E., G. M. Cox, W. A. Schell, J. A. Bartlett, and J. R. Perfect. 1996. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 10:263-268.
120. Hennequin, C., M. Labenne, M. Benkerrou, and M. Hambourg. 1994. Fluconazole-resistant Candida albicans in an immunocompetent child. Clin. Infect. Dis. 19:1179-1180. (Letter.)
121. Hibberd, P. L., and R. H. Rubin. 1994. Clinical aspects of fungal infection in organ transplant recipients. Clin. Infect. Dis. 19(Suppl. 1):S33-S40.
122. Hitchcock, C. A., B. J. Andrews, B. G. H. Lewis, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus, abstr. F75, p. 126. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
123. Hitchcock, C. A., R. J. Andrews, B. G. H. Lewis, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Aspergillus, abstr. F74, p. 125. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
124. Hitchcock, C. A., G. W. Pye, G. P. Oliver, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro, abstr. F72, p. 125. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
125. Hochman, L. G., R. K. Scher, M. S. Meyerson, J. L. Cohen, and J. E. Holwell. 1993. The safety and efficacy of oral fluconazole in the treatment of onychomycosis. J. Geriatr. Dermatol. 1:169-172.
126. Improvisi, L., D. Garcia-Hermoso, F. Provost, F. Dromer, and B. Dupont. 1995. Evaluation of two novel antifungal agents, UR-9746 and UR-9751 in the treatment of experimental murine histoplasmosis, abstr. F89, p. 128. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
127. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20:342-347.
128. Jezequel, S. G., M. Clark, S. Cole, K. E. Evans, and P. Wastall. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pre-clinical pharmacokinetics, abstr. F76. p. 126. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
129. Jezequel, S. G., M. Clark, K. E. Evans, S. Roffey, P. Wastall, and R. Webster. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in animals, abstr. F77, p. 126. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
130. Johnson, E. M., D. W. Warnock, J. Luker, S. R. Porter, and C. Scully. 1995. Emergence of azole drug resistance in 24 Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J. Antimicrob. Chemother. 35:103-114.
131. Kauffman, C. A. 1996. Role of azoles in antifungal therapy. Clin. Infect. Dis. 22(Suppl. 2):S148-S153.
132. Kauffman, C. A., and P. L. Carver. 1997. Antifungal agents in the 1990s. Current status and future developments. Drugs 53:539-549.
133. Khardori, N., H. Nguyen, L. C. Stephens, L. Kalvakuntla, B. Rosenbaum, and G. P. Bodey. 1993. Comparative efficacies of cliofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice. Antimicrob. Agents Chemother. 37:729-736.
134. Kirkpatrick, C. H. 1994. Chronic mucocutaneous candidiasis. J. Am. Acad. Dermatol. 31:S14-S17.
135. Koks, C. H. W., P. L. Meenhorst, M. J. X. Hillebrand, A. Bult, and J. H. Beijnen. 1996. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob. Agents Chemother. 40:1935-1937.
136. Koltin, Y., and C. A. Hitchcock. 1997. Progress in the search for new triazole antifungal agents. Curr. Opin. Chem. Biol. 1:176-182.
137. Kriesel, J. D., E. E. Adderson, W. M. I. Gooch, and A. T. Pavia. 1994. Invasive sinonasal disease due to Scopulariopsis Candida: case report and review of scopulariopsosis. Clin. Infect. Dis. 19:317-319.
138. Kung, N., N. Fisher, B. Gunson, M. Hastings, and D. Mutimer. 1995. Fluconazole prophylaxis for high-risk liver transplant recipients. Lancet 345:1234-1235.
139. Kuokkanen, K., and S. Alava. 1992. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J. Dermatol. Treat. 3:115-117.
140. Larsen, R. A., M. Bauer, J. M. Weiner, D. M. Diamond, M. E. Leal, J. C. Ding, M. G. Rinaldi, and J. R. Graybill. 1996. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 40:2178-2182.
141. Larsen, R. A., S. A. Bozzette, B. E. Jones, D. Haghighat, M. A. Leal, D. Forthal, M. Bauer, J. G. Tilles, J. A. McCutchan, and J. M. Leedom. 1994. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19:741-745.
142. Law, D., C. B. Moore, and D. W. Denning. 1997. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Amimicrob. Agents Chemother. 41:2310-2311.
143. Legendre, R., and J. Escola-Macre. 1990. Itraconazole in the treatment of tinea capitis. J. Am. Acad. Dermatol. 23:559-560.
144. LeMoing, V., O. Lortholary, P. Casassus, L. Guillevin, and B. Dupont. 1995. Traitement des aspergilloses par l'itraconazole. Med. Mal. Infect. 25:50-57.
145. Lesher, J. L. J. 1996. Recent developments in antifungal therapy. Dermatol. Clin. 14:163-169.
146. Linden, P., D. J. Kramer, G. Mazariegos, W. Marsh, A. Casavilla, A. Pinna, J. Fung, and S. Kusne. 1996. Low-dose amphotericin B (LDA) for the prophylaxis of serious Candida infections in high-risk liver recipients, abstr. J47, p. 227. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
147. Lortholary, O., and B. Dupont. 1997. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin. Microbiol. Rev. 10:477-504.
148. Lozano-Chiu, M., P. W. Nelson, V. Paetznick, and J. H. Rex. 1997. Activity of voriconazole (VORI) vs. Candida: effects of incubation time, Candida species, and fluconazole (FLU) susceptibility, abstr. E-87, p. 129. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
149. Lutz, J. E., K. V. Clemons, B. H. Aristizabal, and D. A. Stevens. 1997. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. 41:1558-1561.
150. Lutz, J. E., K. V. Clemons, and D. A. Stevens. 1996. Efficacy of SCH 56592 (SCH) in a murine model of systemic coccidioidomycosis, abstr. F100, p. 117. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
151. Lyman, C. A., and T. J. Walsh. 1992. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44:9-35.
152. Maenza, J. R., W. G. Merz, M. J. Romagnoli, J. C. Keruly, R. D. Moore, and J. E. Gallant. 1997. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin. Infect. Dis. 24:28-34.
153. Maesaki, S., S. Kohno, M. Kaku, H. Koga, and K. Kara. 1994. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob. Agents Chemother. 38: 2843-2845.
154. Manavathu, E. K., J. L. Cutright, and P. H. Chandrasekar. 1997. A comparative study of the in vitro susceptibility of amphotericin B-resistant isolates of Aspergillus fumigatus to voriconazole and itraconazole, abstr. E-85, p. 129. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
155. Martin, M. V., J. Yates, and C. A. Hitchcock. 1997. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob. Agents Chemother. 41:13-16.
156. Martins, M. D., and J. H. Rex. 1997. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann. Intern. Med. 126:332-333. (Letter.)
157. Masur, H. 1995. Management of opportunistic infections associated with HIV infection, p. 1280-1294. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
158. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. J. Cooper, and M. G. Rinaldi. 1997. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41:1832-1834.
159. Menichetti, F., M. Fiorio, A. Tosti, G. Gatti, M. B. Pasticci, F. Miletich, M. Marroni, D. Bassetti, and S. Pauluzzi. 1996. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22:838-840.
160. Miller, G. H., D. Lobenberg, B. Antonacci, A. Cacciapuoti, E. L. J. Moss, F. J. Menzel, M. Michalski, C. Norris, R. Parmegiani, T. Yarosh-Tomaine, et al. 1996. In vitro-in vivo correlations for the azole antifungals SCH 56592 (56592), SCH39304 (39304), SCH51048 (51048), fluconazole (FLZ) and itraconazole (ITZ) in candidiasis and aspergillosis, abstr. F94, p. 116. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
161. Minamoto, G. Y., and A. S. Rosenberg. 1997. Fungal infections in patients with acquired immunodeficiency syndrome. Med. Clin. North Am. 81:381-409.
162. 14 demethylation in fungi, abstr. F92, p. 115. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
163. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
164. Murray, P. A., S. L. Koletar, I. Mallegol, J. Wu, and B. L. Moskovitz. 1997. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin. Ther. 19:471-480.
165. Nahas, G. T., and M. Sisto. 1993. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 186:59-61.
166. Nakamura, T., R. Sakai, J. Sonoda, T. Katoh, T. Kaneko, and T. Horie. 1995. ER-30346, a novel antifungal triazole. IV. Pharmacokinetic and toxicological studies in mice, rats, and dogs, abstr. F94, p. 129. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
167. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing of yeast. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
168. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. NCCLS document M27T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
169. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
170. Nelson, M. R., M. Fisher, J. Cartledge, T. Rogers, and B. G. Gazzard. 1994. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 8:651-654.
171. Nguyen, M. H., L. K. Najvar, C. Y. Yu, and J. R. Graybill. 1997. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41:1120-1123.
172. Nguyen, M. H., J. E. J. Peacock, A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
173. Nguyen, M. H., and C. Y. Yu. 1998. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococais neoformans isolates. Antimicrob. Agents Chemother. 42:471-472.
174. Noemir, A., P. Kumari, M. J. Hilbert, D. Loebenberg, A. Cacciapuoti, F. J. Menzel, E. J. Moss, R. Hare, G. H. Miller, M. N. Cayen, et al. 1995. Comparative pharmacokinetics of a new triazole antifungal agent, SCH 56592. in mice, rats, rabbits, dogs, acid cynomolgus monkeys, abstr. F68, p. 124. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
175. Noemir, A. A., P. Kumari, D. Loebenberg, A. Cacciapuoti, R. Hare, G. Miller, S. Sangekar, S. Mahashabde, J. Sequeira, W. A. Vadino, et al. 1996. Unavailability of SCH 56592, a new broad spectrum triazole antifungal agent, from various formulations, abstr. F103, p. 117. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
176. Nolte, F. S-, T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997 Isolation and characterization of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 44:196-199.
177. Norris, S., J. Wheat, D. McKinsey, D. Lancaster, B. Katz, J. Black, M. Driks, R. Baker, K. Israel, D. Traeger, et al. 1994. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am. J. Med. 96:504-508.
178. Noskin, G. A., J. Lee, D. M. Hacek, M. Postelnick, B. E. Reisberg, V. Stosor, S. A. Weitzman, and L. R. Peterson 1996. Molecular typing for investigating an outbreak of Candida krusei. Diagn. Microbiol. Infect. Dis. 26:117-123.
179. Oakley, K. L., C. B. Moore, and D. W. Denning. 1997. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. 41:1124-1126.
180. Oakley, K. L., G. Morrissey, and D. W. Denning. 1997. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1504-1507.
181. Odds, F. C. 1992. Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents. Antimicrob. Agents Chemother. 36:1727-1737.
182. Pappas, P. G., R. W. Bradsher, S. W. Chapman, C. A. Kauffman, A. Dine, G. A. Cloud, W. E. Dismukes, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 1995. Treatment of blastomycosis with fluconazole: a pilot study. Clin. Infect. Dis. 20:267-271.
183. Parmegiani, R., A. Cacciapuoti, D. Loebenberg, B. Antonacci, C. Norris, T. Yarosh-Tomaine, M. Michalski, R. S. Hare, and G. H. Miller. 1995. Efficacy of SCH 56592 in topical infection models, abstr. F67, p. 124. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
184. Patterson, B. E., and P. E. Coates. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man, abstr. F78, p. 126. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
185. Patterson, B. E., S. Roffey, S. G. Jezequel, and B. Jones. 1995. UK-109,496, a novel, wide-spectrum tirazole derivative for the treatment of fungal infections: disposition in man, abstr. F79, p. 126. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
186. Patterson, T. F., W. R. Kirkpatrick, R. K. Mcatee, and D. Loebenberg. 1996. Efficacy of SCH 56592 in a rabbit model of invasive aspergillosis, abstr. F98, p. 116. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
187. Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40:1910-1913.
188. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl. 2):S89-S94.
189. Pfaller, M. A., M. Bale, G. Buschelman, M. Lancaster, A. Espinel-Ingroff, J. H. Rex, and M. G. Rinaldi. 1994. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for clinical Laboratory Standards proposed standard methods. J. Clin. Microbiol. 32:1650-1653.
190. Pfaller, M. A., and A. L. Barry. 1994. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J. Clin. Microbiol. 32:1992-1996.
191. Pfaller, M. A., L. Burmeister, M. S. Bartlett, and M. G. Rinaldi. 1988. Multicenter evaluation of four methods of yeast inoculum preparation. J. Clin. Microbiol. 26:1437-1441.
192. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole, Sch56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Sacchammyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
193. Pfaller, M. A., J. H. Rex, and M. G. Rinaldi. 1997. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin. Infect. Dis. 24:776-784.
194. Pfaller, M. A., M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B. A. Body, A. Espinel-Ingroff, R. A. Fromtling, G. S. Hall, C. E. Hughes, F. C. Odds, et al. 1990. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob. Agents Chemother. 34:1648-1654.
195. Phillips, P., J. Zemcov, W. Mahmood, J. S. G. Montaner, K. Craib, and A. M. Clarke. 1996. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 10:1369-1376.
196. Powderly, W. G. 1994, Fungi, p. 345-357. In S. Broder. T. C. Merigan, Jr., and D. Bolognesi (ed.), Textbook of AIDS medicine. The Williams & Wilkins Co., Baltimore, Md.
197. Powderly, W. G. 1994. Resistant candidiasis. AIDS Res. Hum. Retroviruses 10:925-929.
198. Powderly, W. G. 1996. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22(Suppl. 2):S119-S123.
199. Powderly, W. G., D. M. Finkelstein, J. Feinberg, P. Frame, W. He, C. Ven der Horst, S. L. Koletar, M. E. Eyster, J. Carey, H. Waskin, et al. 1995. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332:700-705.
200. Powderly, W. G., M. S. Saag, G. A. Cloud, P. Robinson, R. D. Meyer, J. M. Jacobson, J. R. Graybill, A. M. Sugar, V. J. McAuliffe, S. E. Follansbce, et al. 1992. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326:793-798.
201. Prentice, A. G., D. W. Warnock, S. A. N. Johnson, M. J. Phillips, and D. A. Oliver. 1994. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J. Antimicrob. Chemother. 34:247-252.
202. Prentice, A. G., D. W. Warnock, S. A. N. Johnson, P. C. Taylor, and D. A. Oliver. 1995. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J. Antimicrob. Chemother. 36:657-663.
203. Quart, A., A. Espinel-Ingroff, and D. Reich. 1995. Fluconazole for refractory oropharyngeal candidaisis in AIDS patients. AIDS Patient Care 9:56-59.
204. Quart, A. M., A. Espinel-Ingroff, L. Steele Moore, and D. Reich. 1996. Evaluation of fluconazole in the treatment of oropharyngeal candidiasis in patients with AIDS. Infect. Med. 13:708-713.
205. Quindós, G., F. Cabrera, M. del Carmen Arilla, A. Burgos, R. Ortiz-Vigón, J. L. Cañón, and J. Pontón. 1994. Fatal Candida famata peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis who was treated with fluconazole. Clin Infect Dis. 18:658-660. (Letter.)
206. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
207. Report of an International Multicenter Trial. 1989. A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis. Br. J. Obstet. Gynaecol. 96:226-232.
208. Restrepo, A. 1995. Paracoccidioides brasiliensis, p. 2386-2389. In G. L. Mandell. J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
209. Restrepo, M., L. Najvar, F. Barchiesi, and J. R. Graybill. 1995. Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746, abstr. F87, p. 128. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
210. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, O. P. Dib, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, S. G. Hilsenbeck, and T. F. Patterson. 1998. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am. J. Med. 105:7-11.
211. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, O. P. Dib, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, and T. F. Patterson. 1996. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 174:821-827.
212. Rex, J. H. 1995. Sporothrix schenckii, p. 2321-2324. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
213. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. Van Der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheid, A. W. Karchmer, A. P. Dine, et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
214. Rex, J. H., C. R. J. Cooper, W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a brothbased system. Antimicrob. Agents Chemother. 39:906-909.
215. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
216. Rex, J. H., M. A. Pfaller, A. L. Barry, P. W. Nelson, and C. D. Webb, for the NIAID Mycoses Study Group and the Candidemia Study Group. 1995. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 39:40-44.
217. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
218. Rex, J. H., M. A. Pfaller, M. Lancaster, F. C. Odds, A. Bolstrom, and M. G. Rinaldi. 1996. Quality control guidelines for National Committee for Clinical Laboratory Standards-recommended broth macrodilution testing of ketoconazole and itraconazole. J. Clin. Microbiol. 34:816-817.
219. Rex, J. H., M. A. Pfaller, M. G. Rinaldi, A. Polak, and J. Galgiani. 1993. Antifungal susceptibility testing. Clin. Microbiol. Rev. 6:367-381.
220. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
221. Reynes, J., C. Bazin, F. Ajana, A. Datry, J.-P. Le Moing, E. Chwetzoff, and J.-C. Levron. 1997. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob. Agents Chemother. 41:2554-2558.
222. Rhunke, M., A. Schmidt-Westhausen, and M. Trautmann. 1997. In vitro activities of voriconazole (UK-109,486) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:575-577.
223. Roberts, D. T. 1994. Oral therapeutic agents in fungal nail disease. J. Am. Acad. Dermatol. 31:S78-S81.
224. Roseeuw, D., and P. De Doncker. 1993. New therapeutic concepts for the treatment of onychomycosis. J. Eur. Acad. Dermatol. Venereol. 2(Suppl. 1):S34-S38.
225. Ryder, N. S., and I. Leitner. 1997. Synergy between terbinafine and fluconazole against azole-and multidrug-resistant Candida isolates, abstr. E-70, p. 126. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
226. Saag, M. S., G. C. Cloud, J. R. Graybill, J. Sobel, C. Tuazon, B. Wiesinger, L. Riser, B. L. Moskovitz, W. E. Dismukes, and the NIAID Mycoses Study Group (MSG). 1995. Comparison of fluconazole (FLU) versus itraconazole (ITRA) as maintenance therapy of AIDS-associated cryptococcal meningitis (CM), abstr. 1218, p. 244. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
227. Saag, M. S., W. G. Powderly, G. A. Cloud, P. Robinson, M. H. Grieco, P. K. Sharkey, S. E. Thompson, A. M. Sugar, C. U. Tuazon, J. F. Fisher, et al. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl. J. Med. 326:83-89.
228. Sanati, H., P. Belanger, R. Fratti, and M. Ghannoum. 1997. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother. 41:2492-2496.
229. Sanati, H., C. F. Ramos, A. S. Bayer, and M. A. Ghannoum. 1997. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob. Agents Chemother. 41:1345-1348.
230. Sanche, S. E., A. W. Fothergill, and M. G. Rinaldi. 1997. Interspecies variation of the susceptibility of Fusarium species to Schering 56592 in vitro, abstr. E-66, p. 125. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
231. Savin, R. 1996. Diagnosis and treatment of tinea versicolor. J. Fam. Pract. 43:127-132.
232. Schaffner, A., and P. G. Frick. 1985. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J. Infect. Dis. 151:902-910.
233. Schuman, P., L. Capps, G. Peng, J. Vazquez, W. El-Sadr, A. I. Goldman, B. Alston, C. L. Besch, A. Vaughn, M. A. Thompson, M. N. Cobb, T. Kerkering, and J. D. Sobel, for the Terry Beirn Community Programs for Clinical Research on AIDS. 1997. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 126:689-696.
234. Sharkey-Mathis, P. K., C. A. Kauffman, J. R. Graybill, D. A. Stevens, J. S. Hostetler, G. Cloud, W. E. Dismukes, and the NIAID Mycoses Study Group. 1993. Treatment of sporotrichosis with itraconazole. Am. J. Med. 95:279-285.
235. Sharkey-Mathis, P. K., J. Velez, R. Fetchick, and J. R. Graybill. 1993. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J. Acquired Immune Defic. Syndr. 6:809-819.
236. Sheehan, D. J., A. Espinel-Ingroff, L. Steele Moore, and C. D. Webb. 1993. Antifungal susceptibility testing of yeasts: a brief overview. Clin. Infect. Dis. 17(Suppl. 2):S494-S500.
237. Sobel, J. D. 1992. Fluconazole maintenance therapy in recurrent vulvovaginal candidiasis. Int. J. Gynaecol. Obstet. 37(Suppl. 1): 17-24.
238. Sobel, J. D. 1994. Controversial aspects in the management of vulvovaginal candidiasis. J. Am. Acad. Dermatol. 31:S10-S13.
239. Sobel, J. D., D. Brooker, G. E. Stein, J. L. Thomason, D. P. Wermeling, B. Bradley, L. Weinstein, and the Fluconazole Vaginitis Study Group. 1995. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Am. J. Obstet. Gynecol. 172:1263-1268.
240. Stary, A., J. Soeltz-Szoets, C. Ziegler, G. R. Kinghorn, and R. B. Roy. 1996. Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with Candida balanitis. Genitourin. Med. 72:98-102.
241. Stein, G. E., and N. Mummaw. 1993. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob. Agents Chemother. 37:89-92.
242. Stein, G. E., N. L. Mummaw, and S. L. Schooley. 1996. Prevention of recurrent vaginal candidiasis with weekly terconazole cream. Ann. Pharmacother. 30:1080-1083.
243. Stevens, D. A. 1995. Coccidioides immitis, p. 2365-2375. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.). Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
244. Stevens, D. A., M. J. Devine, M. Martinez, and B. Aristizabal. 1995. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 (U46) and UR-9751 (U51): comparison with fluconazole (F), abstr. F 85, p. 127. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
245. Stevens, D. A., and J. Y. Lee. 1997. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch. Intern. Med. 157:1857-1862.
246. Sugar, A. M. 1995. Use of amphoterbin B with azole antifungal drugs: what are we doing? Antimicrob. Agents Chemother. 39:1907-1912.
247. Sugar, A. M., C. A. Hitchcock, P. F. Troke, and M. Picard. 1995. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Cheniother. 39:598-601.
248. Sugar, A. M., and X.-P. Liu. 1995. In vitro activity of SCH 56592 against Blastomyces dermatitidis (Bd), abstr. F65, p. 124. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
249. Sugar, A. M., X.-P. Liu, and R.-J. Chen. 1997. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob. Agents Chemother. 41:2518-2521.
250. Takashima, K., and T. Oki. 1996. Azole antifungal agents. Exp. Opin. Ther. Patients 6:645-654.
251. Timonen, H. 1992. Shorter treatment for vaginal candidosis: comparison between single-dose oral fluconazole and three-day treatment with local micnoazole. Mycoses 35:317-320.
252. Tollemar, J., K. Höckerstedt, B-G Ericzon, H. Jalanko, and O. Ringden. 1995. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 59:45-50.
253. Tomberlin, M. G., G. Baingana, R. Grant, E. K. Mbidde, and M. A. Sande. 1994. Fluconazole with and without flucytosine for AIDS related cryptococcal meningitis in Uganda, abstr. M71, p. 247. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
254. Troke, P. F., K. W. Brammer, C. A. Hitchcock, S. Yonren, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrurn triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC), abstr. F73, p. 125. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
255. Tucker, R. M., D. W. Denning, B. Dupont, and D. A. Stevens. 1990. Itraconazole therapy for chronic coccidioidal meningitis. Ann. Intern. Med. 112:108-112.
256. U.S. Public Health Service/Infectious Disease Society of America. 1995. Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin. Infect. Dis. 21(Suppl. 1):S32-S43.
257. Venkateswarlu, K., M. Taylor, N. J. Manning, M. G. Rinaldi, and S. L. Kelly. 1997. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:748-751.
258. Verweij, P. E., M. Mensink, A. J. Rijs, J. P. Donnelly, J. F. Meis, and D. W. Denning. 1997. In vitro activity of amphotericin B, itraconazole and voriconazole against 151 clinical and environmental Aspergillus fumigatus isolates, abstr. E-90, p. 129. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
259. Walsh, T. J., C. Gonzalez, C. A. Lyman, S. J. Chanock, and P. A. Pizzo. 1996. Invasive fungal infectious in children: recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis. 11:187-290.
260. Walsh, T. J., J. Hitmenz, and P. A. Pizzo. 1994. Editorial response: evolving risk factors for invasive fungal infections - all neutropenic patients are not the same. Clin. Infect. Dis. 18:793-798.
261. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522.
262. Wheat, J. 1995. Endemic mycoses in AIDS: a clinical review. Clin. Microbiol. Rev. 8:146-159.
263. Wheat, J., C. Bick, P. Connolly, M. Smedema, M. Durkin, S. Kohler, and D. Loebenberg. 1996. Comparison of a new triazole. Schering 56592, with itraconazole and amphotericin B for treatment of murine histoplasmosis, abstr. F 101, p. 117. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
264. Wheat, J., R. Hafner, A. H. Korzun, M. T. Limjoco, P. Spencer, R. A. Larsen, F. M. Hecht, W. Powderly, and the AIDS Clinical Trial Group. 1995. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Med. 98:336-342.
265. Wheat, J., R. Hafner, M. Wulfsohn, P. Spencer, K. Squires, W. Powderly, B. Wong, M. Rinaldi, M. Saag, R. Hamill, et al. 1993. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 118:610-616.
266. Wheat, J., P. Marichal, H. Vanden Bossche, A. Le Monte, and P. Connolly. 1997. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob. Agents Chemother. 41:410-414.
267. White, A., and M. B. Goetz. 1995. Candida parapsilosis prosthetic joint infection unresponsive to treatment with fluconazole Clin. Infect. Dis. 20:1068-1069, (Letter.)
268. White, M. H. 1996. Is vulvovaginal candidiasis an AIDS-related illness? Clin. Infect. Dis. 22(Suppl. 2):S124-S127.
269. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
270. Wilcox, C. M., R. O. Darouiche, L. Laine, B. L. Moskovitz, I. Mallegol, and J. Wu. 1997. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis, cyclodextrin. J. Infect. Dis. 176:227-232.
271. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
272. Winn, R. E., J. Anderson, J. Piper, N. E. Aronson, and J. Pluss. 1993. Systemic sporotrichosis treated with itraconazole. Clin. Infect. Dis. 17:210-217.
273. Yamada, H., T. Watanabe, K. Kato, and H. Mochizuki. 1997. Fungicidal mechanisms of action of D0870 against Ctyptococcus neoformans under acidic conditions. Antimicrob. Agents Chemother. 41:2710-2713.
274. Yotsuji, A., K. Shimizu, H. Araki, K. Fujimaki, N. Nishida, R. Hori, N. Annen, S. Yamamoto, H. Hayakawa, H. Imaizumi, et al. 1997. T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations. Antimicrob. Agents Chemother. 41:30-34.